Extremely low gestational age infants' PARAcetamol Study
- Conditions
- Open ductus arteriosus of a premature infantTherapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
- Registration Number
- EUCTR2018-000566-11-FI
- Lead Sponsor
- niversity of Oulu
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 40
All extremely premature (born before 28 gestation weeks) or low birth weight (< 1000 g) infants treated in neonatal intensive care unit of Oulu University Hospital and who have an open ductus
Are the trial subjects under 18? yes
Number of subjects for this age range: 40
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
- Denial by the parents
- Severe congenital or chromosomal anomaly or severe clinical situation, that complicates the standard ductal therapies e.g. asphyxia, or persistent pulmonary hypertension of a newborn
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: To study the efficacy and safety of intravenous paracetamol in contracting ductus arteriosus of a very premature (<28 gestation weeks) or extremely low birth weight (<1000 g) infants ;Secondary Objective: Not applicable;Primary end point(s): Shortening of the ductal closure time;Timepoint(s) of evaluation of this end point: - after the study drug period<br>- at the discharge from the NIC
- Secondary Outcome Measures
Name Time Method Secondary end point(s): Cardiac ultrasound findings, ductal therapies, duration of the ventilation assist, paracetamol serum concentrations, possible paracetamol side effects, complications of prematurity, neonatal and long term morbidity and mortality ;Timepoint(s) of evaluation of this end point: - discharge to home